Abstract:PURPOSE:Pancreatic cancer is a highly aggressive disease that remains refractory to various chemotherapeutic agents. Because the proto-oncogene c-myc can modulate apoptosis in response to cytotoxic insults and is commonly overexpressed in pancreatic cancer, we investigated the value of c-myc as a potential modulator of cellular response to various chemotherapeutic agents.EXPERIMENTAL DESIGN:Stable overexpression or small interfering RNA (siRNA)-mediated knockdown of c-myc and restoration of cyclin D1 were done in the Ela-myc pancreatic tumor cell line. Cell viability after cisplatin treatment of c-myc-overexpressing, control, and siRNA-transfected cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and drug-induced apoptosis was measured by DNA fragmentation, sub-G(1), and poly(ADP-ribose) polymerase cleavage analyses. Protein expression profile after cisplatin treatment was determined by Western blotting and DNA binding activity of nuclear factor-kappaB was examined by electrophoretic mobility shift assay.RESULTS:Ectopic overexpression of c-myc in murine and human pancreatic cancer cell lines, Ela-myc and L3.6pl, respectively, resulted in increased sensitivity to cisplatin and other chemotherapeutic drugs. Increased sensitivity to cisplatin in c-myc-overexpressing cells was due, in part, to the marked increase in cisplatin-induced apoptosis. Conversely, down-regulation of c-myc expression in stable c-myc-overexpressing cells by c-myc siRNA resulted in decreased sensitivity to cisplatin-induced cell death. These results indicate an important role of c-myc in chemosensitivity of pancreatic cancer cells. The c-myc-induced cisplatin sensitivity correlated with inhibition of nuclear factor kappaB activity, which was partially restored by ectopic cyclin D1 overexpression.CONCLUSIONS:Our results suggest that the c-myc-dependent sensitization to chemotherapy-induced apoptosis involves suppression of cyclin D1 expression and nuclear factor kappaB activity.

Molecular Insights of c-Myc in Cellular Senescence

C-Myc-induced Chemosensitization is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-Kappa B Activity in Pancreatic Cancer Cells.

Cellular senescence and aging: the role of B-MYB

Irreversible cell cycle exit associated with senescence is mediated by constitutive MYC degradation

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Cellular Senescence and Anti-Cancer Therapy.

A c-Myc–SIRT1 feedback loop regulates cell growth and transformation

Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis

The dual role of cellular senescence in human tumor progression and therapy

BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21(CIP1) pathway.

Seeking for cellular senescence associated genes

Cellular senescence: Molecular mechanisms and pathogenicity

C-Myc Overexpression is Required for Continuous Suppression of Oncogene-Induced Senescence in Melanoma Cells

Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity

Cellular senescence: when bad things happen to good cells

Cellular Senescence and Tumor Therapy

Cellular senescence: a double-edged sword in cancer therapy

Cellular senescence in cancer: molecular mechanisms and therapeutic targets

The P53/mirnas/ccna2 Pathway Serves As a Novel Regulator of Cellular Senescence: Complement of the Canonical P53/p21 Pathway

The Function and Molecular Mechanism of Cellular Senescence-Inhibited Gene